The medical devices auxiliary of Johnson & Johnson, is devoted to leading the way in resolving the burden of obesity for health care systems and patients all over the world, by increasing access and establishing the critical value of therapy.
The DSS-II recommendations are an actual business changer since they adequately establish surgery, for the earliest time, as a standard diabetes therapy option. This conclusion is recommended by 45 global organizations, an exceptional level of agreement in the medical community.
As strong supporters of proof-based therapy, Ethicon appreciates the publication of new research proposing that surgery could play a relevant role in the treatment of patients undergoing distress with type 2 diabetes. Latest guidelines, published in Diabetes Care, and delivered at a podium presentation throughout the recent yearly American Diabetes Association (ADA) Scientific meetings, state that metabolic surgery should be considered for the therapy of diabetes type 2 in patients with obesity i.eBMI >30 kg/m2 or > 27.5 for patients of Asian descent when hyper-glycaemia is insufficiently controlled by lifestyle and maximum medical therapy. The guidelines are recommended by 45 worldwide societies ( that is 30 medical and 15 surgical organizations) at the time of publication, including the American Diabetes Federation ,International Diabetes Federation and Diabetes UK.
The guidelines are supported by clinical and mechanistic proof including 11 casual clinical trials. In further support for these conclusions, the final, five year follow up data from Surgical Therapy and Medications Potentially Eradicate Diabetes Efficiently clinical test, braces the part of surgery for the treatment of overweight patients with type 2 diabetes. The discoveries, which were talked about during the European Obesity Summit in Gothenburg sometime this month, show that bariatric surgery's useful effects on blood glucose control in relatively obese patients with type 2 diabetes may continue for likely five years. Moreover, patients who got bariatric surgery can control their diabetes type 2 over time related to intensive medical therapy alone.
At the symposium, professor of surgery and leader of Metabolic and Bariatric Surgery, King’s College London, Dr Rubino Francesco commented that while prevention of diabetes prevails as the utmost importance, patients with established disease should have access to effective therapy options; evidence has proved that surgery can be the best choice for some people with type 2 diabetes. He also said that the DSS-II guidelines are the actual game changer because they effectively establish surgery, as a standard diabetes therapy option. This conclusion is recommended by 45 global organizations, an unprecedented level of agreement in the medical community.
The conference also focused attention on a report developed together with the Economist Intelligence Unit which studied the present national and EU-level methods to obesity policy, recognizing weaknesses in present attempts across Europe.
Silvia De Domonicis, Ethicon Franchise VP EMEA said that a more holistic and cost effective strategy is needed to tackle obesity. Also said that what’s important now is that the member states of Europe collectively recognize that those going through pains or distress from obesity should be treated as patients. And they expect that this recent research aids to initiate a crucial conversation with policymakers in order to aid shape the future of obesity management.
Obesity and metabolic disease have reached pandemic percentage, as almost 30 percent of the world’s population , 2.1 billion people are overweight. As obesity rates have escalated, so also have those for type 2 diabetes, and 25-27 percent of the obese population has type 2 diabetes. Meanwhile, it is estimated in Europe that 20 percent of the adult population is obese, and this has relevant economic implications with at least €33 billion annual health care costs being attributed to obesity.
Post a Comment